[Anemia and lung cancer].
Erythopoietin (EPO) treatment of anemia during cancer has dramatically improved the tolerance of chemotherapy and quality of life of patients at all stages of the disease. Several surveys have demonstrated a high prevalence and a high incidence of anemia in lung cancer patients. The guidelines updates concerning EPO treatment for these patients are described. They take into account the debate concerning the potential harm of these molecules on the neoplastic disease and the possible role of EPO receptors expressed by several tumors, including non small cell lung cancer.
Bréchot
J-M
JM
Service d'Oncologie Médicale, Hôpital Avicenne, Université Paris-XIII, AP-HP, 125 Route de Stalingrad, 93009 Bobigny Cedex, France. jeanne-marie.brechot@avc.ap-hop-paris.fr
Morère
J-F
JF
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D017410:Practice Guidelines as Topic; D011788:Quality of Life / Q000523:psychology; D011994:Recombinant Proteins; D012307:Risk Factors
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D004921:Erythropoietin